That performance is even stronger than it might initially seem considering the S&P 500 index dropped 8.2% last month due to concerns that the novel coronavirus, COVID-19, could blunt global economic growth.
Dexcom stock is up a whopping 95.1% over the one-year period through March 5, compared to the broader market's 10.6% return over this period.
We can attribute Dexcom stock's strong performance last month to the healthcare company's Feb. 13 release of fourth-quarter 2019 results that pleased investors. Shares soared 12.6% the next day.
In Q4, revenue jumped 37% year over year to $462.8 million, driven by the continued robust demand from people living with diabetes for the company's G6 continuous glucose monitoring (CGM) systems. That result easily topped the $442.4 million Wall Street consensus estimate. Adjusted earnings came in at $106.5 million, or $1.15 per share, up from $50.2 million, or $0.56 per share, in the year-ago period. That result also sprinted by the analyst expectation, which was $0.74.
Dexcom reaffirmed its guidance for full-year 2020. It expects revenue of $1.73 billion to $1.78 billion, representing growth of 17% to 20% year over year. It also projects adjusted operating margin of approximately 13%, compared to 10.9% in 2019.